Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from LLY

3 Dividend-Paying Stocks to Consider During a Recession

Rising inflation, the Fed’s hawkish stance to tame it, and an economic contraction for two consecutive quarters have stoked fears of a recession in the U.S. economy. Amid the likely economic downturn, investors could consider investing in stocks that provide a steady income in the form of dividends. Therefore, we…

StockNews.com

Watch These Leaders With Earnings Due, Buy Zones In Focus

With earnings due, IBD Leaderboard stocks like Eli Lilly, Vertex and Ollie's test bases, breakouts and buy zones.

Investors Business Daily

Is Biotech Ready for Another Bull Run? 3 Stocks to Get in Ahead of the Crowd

The biotech industry flourished during the height of the COVID-19 pandemic and reported record revenues and earnings last year. Despite the market slowdown, the sector is poised for another bull run, given the continued global fight against COVID-19 and the increasing demand with an aging population. Popular biotech stocks Pfizer…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

LLY Stock Another Example Of Medical Sector Strength

Medical sector stocks are offering the most compelling setups right now. Here's how we handled our latest trade for profit.

Investors Business Daily

2 Biotech Stocks Crushing It During the Market Crash

The Biotech industry has gained significant momentum since the pandemic. Moreover, the industry’s prospects look bright amid the lucrative federal funding and solid investments in breakthrough developments. Thus, given the stock market volatility, it could be wise to invest in quality biotech stocks Eli Lilly (LLY) and Jazz Pharmaceuticals (JAZZ),…

StockNews.com

What Are Whales Doing With Eli Lilly

A whale with a lot of money to spend has taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 14 strange trades.

Benzinga

If You Invested $100 In This Stock 5 Years Ago, You Would Have $400 Today

Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 21.93% on an annualized basis producing an average annual return of 31.32%. Currently, Eli Lilly has a market capitalization of $307.03 billion.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

This Is What Whales Are Betting On Eli Lilly

A whale with a lot of money to spend has taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 17 strange trades.

Benzinga

LLY's New Drug Lineup Looks Promising For Investors

Eli Lilly and Company’s (LLY) new drug line-up is expected to generate higher revenues and earnings. Also, LLY’s robust earnings, favorable analyst estimates, and higher-than-industry profitability make it a promising investment option. Read on….

StockNews.com

Dow Jones Futures: New Market Rally Struggles For Direction; 5 Stocks Near Buy Points

The market rally rebounded from losses but gains faded. Five stocks from a hot sector are near buy points.

Investors Business Daily

Dow Jones Futures Fall After Market Rallies; Here Comes Fed Chief Powell

A market rally attempt gained steam as Tesla jumped but investors should be wary. Fed chief Jerome Powell is on tap again.

Investors Business Daily

5 Stocks Upgraded To "Strong Buy" Last Week

Investors’ concerns over the impending interest rate hikes are expected to keep the markets highly volatile in the near term. Therefore, it could be wise to invest in fundamentally-sound stocks Group 1 Automotive (GPI), Eli Lilly and Company (LLY), nVent Electric (NVT), Primo Water (PRMW), and Sanmina (SANM) that are…

StockNews.com

Dow Jones Futures Jump, Bitcoin Above $20,000; Beware The Bear Market

Futures rose as Bitcoin rebounded. It's a bear market, so stay safe. Tesla rival BYD is among a few stocks setting up.

Investors Business Daily

If You Invested $1000 In This Stock 15 Years Ago, You Would Have $5,000 Today

Eli Lilly (NYSE:LLY) has outperformed the market over the past 15 years by 5.21% on an annualized basis producing an average annual return of 11.42%. Currently, Eli Lilly has a market capitalization of $273.33 billion.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Dow Jones Futures Dive, Yields Hit Multiyear Highs As Stagflation Risks Grow

Futures plunge, yields jump and Bitcoin dives as markets mull stagflation risks and a supersized Fed rate hike this week.

Benzinga

Looking At Eli Lilly's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 35 strange trades.

Investors Business Daily

We're Looking At Obesity In A New Way — And 4 Pharmaceutical Stocks Could Benefit

A group of pharmaceutical stocks are climbing as they pivot their diabetes drugs to help treat obesity. A potential multibillion-dollar market beckons them.

Investors Business Daily

Dow Jones Futures Rise After Many Market Rally Leaders Crack; Tesla China Sales Ramping Up

Dow Jones futures: Indexes held support Wednesday, but market rally leaders sold off. Tesla China sales rose in May, but still ramping up.

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Growth Stocks to Buy if You Think Inflation Has Peaked

A slightly lower consumer price index in April and expectations of a flat or lower CPI in May indicate inflation may have peaked. Yesterday, the major U.S. stock indices increased slightly as leading growth stocks rallied. Given this backdrop, we think it could be wise to invest in the shares…

Benzinga

In Eli Lilly's Lebrikizumab Atopic Dermatitis Study, Majority Of Patients Maintained Skin Clearance At One Year

Eli Lilly And Co (NYSE:LLY) announced topline results from one-year analyses of the efficacy and safety of lebrikizumab for moderate-to-severe atopic dermatitis (AD). The new findings from the Phase 3 trials (ADvocate 1 and 2) showed that 8/10 of patients who achieved clinical response with lebrikizumab monotherapy at 16 weeks maintained skin clearance…

Benzinga

Eli Lilly Presents New Analyses On Tirzepatide Injection For Type 2 Diabetes

Eli Lilly And Co (NYSE:LLY) presented new data from a mechanism of action study and new analyses of the global registration program for Mounjaro (tirzepatide) injection at the American Diabetes Association. At 28 weeks, participants taking Mounjaro (N=45) had significantly greater reductions in weight and fat mass compared to Novo Nordisk A/S's (NYSE:NVO) injectable Ozempic…

Investors Business Daily

Eli Lilly Flirts With Buy Point On A 'Flawless' Update For Its Diabetes-Turned-Obesity Drug

Eli Lilly delivered a promising update for its experimental obesity treatment over the weekend, leading LLY stock to pop Monday.

Investors Business Daily

Northrop Grumman, Eli Lilly Lead 5 Stocks Near Buy Points Geared For This Economy

Eli Lilly and Northrop Grumman lead five stocks near buy points that are solid bets to withstand the coming Federal Reserve-induced slowdown.

Benzinga

Looking At Eli Lilly's Recent Whale Trades

Someone with a lot of money to spend has taken a bearish stance on Eli Lilly (NYSE:LLY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Investors Business Daily

Stock Market Closes Sharply Higher As Key Inflation Rate Lower Than Expected; Tesla, Boeing, Apple Lead Indexes

The stock market extended its rally to a third day as a key inflation rate came in lower than expected. Tesla, Apple, Boeing led.

1 … 7 8 9 10

People

Dipanjan BanchurSince

722 stories

Umer Raffat

16 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.